Plus Therapeutics Presents Positive Data from Ongoing ReSPECT Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases (GlobeNewswire) - Aug 13, 2022 - P1/2 | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "The oral presentation, titled Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases Phase 1/2a Dose Escalation Trial [LOCL-04], demonstrated that the 186RNL dose administered through an intraventricular catheter at 6.6 mCi in 5.0 mL achieved absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid space, which was well tolerated with no treatment-related adverse events of greater than grade 1....Importantly, all patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 65% to 92% which was also durable."
P1/2 data • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|